Back to Authors

Fryer, James P.

Mayo Clinic

Mayo Clinic

Citations 45

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
Jitprapaikulsan, Jiraporn , Fryer, James P., Majed, Masoud , Jenkins, Sarah M. , Cabre, Philippe, Hinson, Shannon R., Weinshenker, Brian G. , Mandrekar, Jay , Chen, John J. , Lucchinetti, Claudia F. , Jiao, Yujuan , Segan, Jessica, Schmeling, John E., Mills, John R. , Pittock, Sean J. , Smith, Carin Y. , Weinshenker, Brian G , Pittock, S J , Chen, John J , Flanagan, Eoin P. , McKeon, Andrew

Neurology Neuroimmunology & Neuroinflammation | May 28, 2020 | Volume: 7 | Issue: 4 | Pages: No page available

10.1212/nxi.0000000000000727 Get It

Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica
Burt, Richard K. , Balabanov, Roumen , Han, Xiaoqiang , Burns, Carol, Gastala, Joseph B. , Jovanovic, Borko, Helenowski, Irene , Jitprapaikulsan, Jiraporn , Fryer, James P., Pittock, Sean J. , Gastala, Joseph , Pittock, S J

Neurology | October 2, 2019 | Volume: 93 | Issue: 18 | Pages: No page available

10.1212/wnl.0000000000008394 Get It

Autoimmune septin-5 cerebellar ataxia
Honorat, Josephe A., López‐Chiriboga, A. Sebastian , Kryzer, Thomas J., Fryer, James P., Devine, Michelle F., Flores, Angela, Lennon, Vanda A. , Pittock, Sean J. , McKeon, Andrew , Devine, Michelle, Pittock, S J , McKeon, Andrew

Neurology Neuroimmunology & Neuroinflammation | July 9, 2018 | Volume: 5 | Issue: 5 | Pages: No page available

10.1212/nxi.0000000000000474 Get It

Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis
Jitprapaikulsan, Jiraporn , López‐Chiriboga, A. Sebastian , Fryer, James P., McKeon, Andrew , Weinshenker, Brian G. , Pittock, Sean J. , Pittock, S J , Weinshenker, Brian G , McKeon, Andrew , Flanagan, Eoin P.

JAMA Neurology | April 28, 2018 | Volume: 75 | Issue: 7 | Pages: 892

10.1001/jamaneurol.2018.0805 Get It

Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4–IgG in Patients in the Optic Neuritis Treatment Trial
Chen, John J. , Majed, Masoud , Jitprapaikulsan, Jiraporn , Fryer, James P., Leavitt, Jacqueline A., McKeon, Andrew , Pittock, Sean J. , Pittock, S J , McKeon, Andrew , Chen, John J , Tobin, W. Oliver , Flanagan, Eoin P.

JAMA Ophthalmology | February 22, 2018 | Volume: 136 | Issue: 4 | Pages: 419

10.1001/jamaophthalmol.2017.6757 Get It

Clinical utility of testing AQP4-IgG in CSF
Majed, Masoud , Fryer, James P., McKeon, Andrew , Lennon, Vanda A. , Pittock, Sean J. , Pittock, S J , McKeon, Andrew

Neurology Neuroimmunology & Neuroinflammation | April 21, 2016 | Volume: 3 | Issue: 3 | Pages: No page available

10.1212/nxi.0000000000000231 Get It

Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum
Flanagan, Eoin P. , Cabre, Philippe, Weinshenker, Brian G. , Sauver, Jennifer L. St. , Jacobson, Debra J., Majed, Masoud , Lennon, Vanda A. , Lucchinetti, Claudia F. , McKeon, Andrew , Matiello, Marcelo , Kale, Nilifur, Wingerchuk, Dean M. , Mandrekar, Jay , Sagen, Jessica, Fryer, James P., Robinson, Angala Borders, Pittock, Sean J. , Sagen, Jessica A., Pittock, S J , Flanagan, E P , Weinshenker, Brian G , St Sauver, Jennifer L , McKeon, Andrew

Annals of Neurology | February 18, 2016 | Volume: 79 | Issue: 5 | Pages: 775-783

10.1002/ana.24617 Get It

ObjectiveNeuromyelitis optica (NMO) and its spectrum disorders (NMOSD) are inflammatory demyelinating diseases (IDDs) with a specific biomarker, aquaporin‐4–immunoglobulin G (AQP4‐IgG). Prior NMO/NMOSD epidemiological studies have been limited by lack of AQP4‐IgG seroprevalence assessment, absence of population‐based USA studies, and under‐representation of blacks. To overcome these limitations, we sought to compare NMO/NMOSD seroepidemiology across 2 ethnically divergent populations.MethodsWe performed a population‐based comparative study of the incidence (2003–2011) and prevalence (on December 31, 2011) of NMO/NMOSD and AQP4‐IgG seroincidence and seroprevalence (sera collected in 80–84% of IDD cases) among patients with IDD diagnosis in Olmsted County, Minnesota (82% white [Caucasian]) and Martinique (90% black [Afro‐Caribbean]). AQP4‐IgG was measured by M1 isoform fluorescence‐activated cell‐sorting assays.ResultsThe age‐ and sex‐adjusted incidence (7.3 vs 0.7/1,000,000 person‐years [p < 0.01]) and prevalence (10 vs 3.9/100,000 [p = 0.01]) in Martinique exceeded that in Olmsted County. The AQP4‐IgG age‐ and sex‐adjusted seroincidence (6.5 vs 0.7/1,000,000 person‐years [p < 0.01]) and seroprevalence (7.9 vs 3.3/100,000 [p = 0.04]) were also higher in Martinique than Olmsted County. The ethnicity‐specific prevalence was similar in Martinique and Olmsted County: 11.5 and 13/100,000 in blacks, and 6.1 and 4.0/100,000 in whites, respectively. NMO/NMOSD represented a higher proportion of IDD cases in Martinique than Olmsted County (16% vs 1.4%; p < 0.01). The onset age (median = 35–37 years) and female:male distribution (5–9:1) were similar across both populations; 60% of prevalent cases were either blind in 1 eye, dependent on a gait aid, or both.InterpretationThis study reports the highest prevalence of NMO/NMOSD in any population (10/100,000 in Martinique), estimates it affects 16,000 to 17,000 in the USA (higher than previous predictions), and demonstrates it disproportionately affects blacks. Ann Neurol 2016;79:775–783